US9849123B2ActiveUtilityA1

Composition and method for treating skin conditions

75
Assignee: 442 VENTURES LLCPriority: Nov 4, 2010Filed: Aug 17, 2017Granted: Dec 26, 2017
Est. expiryNov 4, 2030(~4.3 yrs left)· nominal 20-yr term from priority
Inventors:J. Mark Jackson
A61P 31/12A61P 35/02A61P 43/00A61P 31/20A61P 35/00A61P 17/02A61P 17/12A61P 15/00A61P 1/02A61P 17/00A61K 45/06A61K 31/60A61K 9/0014A61K 31/4745A61K 31/075A61K 31/437A61K 31/4436A61K 31/203A61K 2300/00A61K 9/0019A61K 9/08A61K 31/455A61K 31/07Y02A50/30
75
PatentIndex Score
2
Cited by
2
References
12
Claims

Abstract

Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A composition, comprising: imiquimod at a final concentration between about 8% (wt/wt) and about 0.1% (wt/wt); and tazarotene at a final concentration of about 0.1% (wt/wt) and about 0.001% (wt/wt). 
     
     
       2. The composition of  claim 1 , wherein the tazarotene is provided in the composition at a final concentration of less than about 0.1% (wt/wt) to about 0.001% (wt/wt). 
     
     
       3. The composition of  claim 2 , wherein the imidazoquinoline compound is provided in the composition at a final concentration of less than about 8% (wt/wt) and about 0.1% (wt/wt). 
     
     
       4. The composition of  claim 1 , wherein the tazarotene is provided in the composition at a final concentration of about 0.01% (wt/wt) to about 0.001% (wt/wt). 
     
     
       5. The composition of  claim 4 , wherein the imidazoquinoline compound is provided in the composition at a final concentration of less than about 8% (wt/wt) and about 0.1% (wt/wt). 
     
     
       6. The composition of  claim 1 , wherein the imidazoquinoline compound is provided in the composition at a final concentration of less than about 8% (wt/wt) and about 0.1% (wt/wt). 
     
     
       7. The composition of  claim 1 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:5. 
     
     
       8. The composition of  claim 1 , wherein the ratio of the concentration of tazarotene to the concentration of imiquimod is less than 1:10. 
     
     
       9. The composition of  claim 1 , wherein the composition is prepared for administration to an affected site on the skin and/or mucosal surface of a subject. 
     
     
       10. The composition of  claim 1 , wherein the composition is prepared for topical administration. 
     
     
       11. The composition of  claim 1 , wherein the composition is prepared for administration by intralesional injection. 
     
     
       12. The composition of  claim 1 , wherein the composition is substantially stable at a temperature of 50° C. for a period of four (4) weeks.

Join the waitlist — get patent alerts

Track US9849123B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.